This report provides comprehensive information on the therapeutic development for Celiac Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Celiac Disease and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Celiac Disease Overview
- Therapeutics Development
- Pipeline Products for Celiac Disease - Overview
- Pipeline Products for Celiac Disease - Comparative Analysis
- Celiac Disease - Therapeutics under Development by Companies
- Celiac Disease - Therapeutics under Investigation by Universities/Institutes
- Celiac Disease Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Celiac Disease - Products under Development by Companies
- Celiac Disease - Products under Investigation by Universities/Institutes
- Celiac Disease - Companies Involved in Therapeutics Development
- Alvine Pharmaceuticals, Inc.
- Amgen Inc.
- Amyra Biotech AG
- Avaxia Biologics, Inc.
- Calypso Biotech SA
- enGene, Inc
- F. Hoffmann-La Roche Ltd.
- Glenmark Pharmaceuticals Ltd.
- ImmusanT, Inc.
- Innovate Biopharmaceuticals, Inc.
- Intrexon Corporation
- Zedira GmbH
For more information visit http://www.researchandmarkets.com/research/45f82r/celiac_disease